NCT05151146已完成1 期
A Phase 1 Study to Investigate the Pharmacokinetics of ANJ900 (Metformin Hydrochloride Delayed-release Tablets) and the Effect of Food on the Pharmacokinetics of ANJ900 in Chinese Healthy Subjects
Anji Pharma1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2021年10月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Characterize the AUC of single oral dose of ANJ900 in healthy Chinese subjects
研究概览
简要总结
This will be a Phase 1, randomised, open label, 3 way crossover study in healthy male and female Chinese subjects. Subjects will participate in 3 treatment periods and will be randomised in a 1:1:1 ratio to 1 of 3 treatment sequences. There will be a washout period of 7 days between doses.
详细描述
This will be a Phase 1, randomised, open label, 3 way crossover study in healthy male and female Chinese subjects. Subjects will participate in 3 treatment periods and will be randomised in a 1:1:1 ratio to 1 of 3 treatment sequences. There will be a washout period of 7 days between doses.
All subjects will receive each of the following treatments:
- Treatment 1: A single dose of 1800 mg ANJ900 in the fasted state.
- Treatment 2: A single dose of 1800 mg ANJ900 in the fed state.
- Treatment 3: A single dose of 1000 mg metformin IR in the fasted state. Potential subjects will be screened to assess their eligibility to enter the study within 14 days prior to the first dose administration. Subjects will be admitted into the study site on Days 1, 7, and 14 and will be confined to the study site until discharge on Days 3, 10, and 17 respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Chinese males or females between 18 and 65 years of age, inclusive.
- •Body mass index between 18.5 and 28.0 kg/m2, inclusive, with a body weight >50 kg (males) or >45 kg (females).
- •In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG (including heart rate ≥50 bpm, PR interval <200 ms, and QRS duration <120 ms), vital signs measurements (systolic blood pressure ≥90 and <140 mmHg and diastolic blood pressure ≥50 and <90 mmHg), and clinical laboratory evaluations at screening and Day -1 as assessed by the investigator (or designee).
- •Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Appendix
- •Able to comprehend and willing to sign an ICF, remain at the study site, and to abide by the study restrictions.
排除标准
- •Significant history or clinical manifestation of any metabolic, allergic (eg, asthma, urticaria, eczema dermatitis), dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
- •Malignancy within 5 years (except basal cell skin carcinoma).
- •History of a clinically significant disease that affects drug absorption, metabolism, or elimination processes, as determined by the investigator (or designee), including, but not limited to:
- •inflammatory bowel disease, gastritis, ulcers, bile duct stones, or internal bleeding of the gastrointestinal tract or rectum
- •gastrointestinal surgery (eg, anastomosis or bowel resection)
- •pancreatic injury or pancreatitis
- •urinary tract obstruction or difficulty passing urine.
- •History of hypoglycaemic episodes, severe unconscious hypoglycaemia, or glucose metabolism disorders.
- •History of significant hypersensitivity, intolerance, or allergy to any drug compound (eg, metformin), food, or other substance, unless approved by the investigator (or designee).
- •Active symptoms, or a recent diagnosis of, coronavirus disease-19 (COVID-19).
- •Donation or loss of >500 mL of blood within 4 weeks prior to screening.
- •Receipt of blood products within 8 weeks prior to screening.
- •Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months.
- •Poor peripheral venous access or intolerant of venous blood collection.
- •Use or intend to use any prescription medications (with the exception of paracetamol [≤4000 mg/day] or ibuprofen [≤2400 mg/day]) within 4 weeks or 5 half lives, whichever is longer, prior to screening.
- •Use or intend to use any over the counter medications (with the exception of paracetamol [≤4000 mg/day], ibuprofen [≤2400 mg/day], and topical over the counter medications for external use), herbal medications, or food supplements (eg, vitamins or mineral supplements) within 2 weeks or 5 half lives, whichever is longer, prior to screening.
- •Fasting plasma glucose <3.9 mmol/L or >6.1 mmol/L at screening or Day -
- •Alanine aminotransferase, aspartate aminotransferase, or direct bilirubin >1.5 × the upper limit of normal at screening or Day -
- •Positive hepatitis panel, human immunodeficiency virus test, or syphilis test.
- •History of alcoholism or drug/chemical abuse within 12 months.
- •Alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
- •Have consumed foods and beverages containing caffeine, xanthine, alcohol, or components that affect the absorption, metabolism, and excretion of drugs (eg, grapefruit or Seville oranges) within 48 hours prior to check-in.
- •Have smoked >5 cigarettes or use the equivalent tobacco or nicotine containing products per day in the past 3 months, or are unwilling to abstain from smoking cigarettes or use the equivalent tobacco or nicotine containing products from 48 hours prior to Day -1 until discharge.
- •Are unwilling to abstain from strenuous exercise from 48 hours prior to Day -1 until discharge.
- •Positive alcohol breath test, urine drugs of abuse test, or urine cotinine test.
- •Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
研究组 & 干预措施
ANJ900 in the fasted state
Experimental
Single dose (1800 mg) of ANJ900
干预措施: ANJ900 (Drug)
ANJ900 in the fed state
Experimental
Single dose (1800 mg) of ANJ900
干预措施: ANJ900 (Drug)
Metformin IR in the fasted state
Active Comparator
Single dose (1000 mg) of metformin IR
干预措施: Metformin IR (Drug)
结局指标
主要结局
Characterize the AUC of single oral dose of ANJ900 in healthy Chinese subjects
时间窗: 1 week
ANJ900 levels in blood will be collected in serial draws
Characterize Cmax of a single oral dose of ANJ900 in healthy Chinese subjects
时间窗: 1 week
ANJ900 levels in blood will be collected in serial draws
次要结局
- Characterize the urine excretion from time zero to 24 hours post does of metformin(1 week)
- Assess the safety of ANJ900 in healthy Chinese subjects(3 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Multiple Ascending Dose Study in Healthy VolunteersHealthyNCT02404922Concert Pharmaceuticals30
已完成
1 期
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal ImpairmentRenal ImpairmentNCT02942810Wockhardt48
已完成
1 期
A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese SubjectsHealthy Japanese VolunteersNCT01608542AstraZeneca24
已完成
1 期
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)Infection, Human Immunodeficiency VirusNCT02480894ViiV Healthcare112
已完成
1 期
Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy VolunteersTTR CardiomyopathyNCT01655511Pfizer9